JP2010501576A5 - - Google Patents

Download PDF

Info

Publication number
JP2010501576A5
JP2010501576A5 JP2009525648A JP2009525648A JP2010501576A5 JP 2010501576 A5 JP2010501576 A5 JP 2010501576A5 JP 2009525648 A JP2009525648 A JP 2009525648A JP 2009525648 A JP2009525648 A JP 2009525648A JP 2010501576 A5 JP2010501576 A5 JP 2010501576A5
Authority
JP
Japan
Prior art keywords
day
effective amount
therapeutically effective
use according
therapeutic agent
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009525648A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010501576A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/018770 external-priority patent/WO2008024485A2/en
Publication of JP2010501576A publication Critical patent/JP2010501576A/ja
Publication of JP2010501576A5 publication Critical patent/JP2010501576A5/ja
Pending legal-status Critical Current

Links

JP2009525648A 2006-08-25 2007-08-23 ビタミンｄ化合物及び追加の治療薬の投与を含む癌の治療方法 Pending JP2010501576A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US93492406P 2006-08-25 2006-08-25
PCT/US2007/018770 WO2008024485A2 (en) 2006-08-25 2007-08-23 Methods for treating cancer comprising the administration of a vitamin d compound and an additional therapeutic agent

Publications (2)

Publication Number Publication Date
JP2010501576A JP2010501576A (ja) 2010-01-21
JP2010501576A5 true JP2010501576A5 (enExample) 2010-10-07

Family

ID=39107444

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009525648A Pending JP2010501576A (ja) 2006-08-25 2007-08-23 ビタミンｄ化合物及び追加の治療薬の投与を含む癌の治療方法

Country Status (9)

Country Link
EP (2) EP2425874A3 (enExample)
JP (1) JP2010501576A (enExample)
KR (1) KR20090060306A (enExample)
CN (1) CN101528309A (enExample)
AU (1) AU2007287099A1 (enExample)
CA (2) CA2838089A1 (enExample)
IL (1) IL197212A0 (enExample)
NO (1) NO20091191L (enExample)
WO (1) WO2008024485A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1007415A2 (pt) * 2009-01-27 2016-02-16 Berg Biosystems Llc vitamina d3 e análogos da mesma para aliviar os efeitos colaterais associados com quimioterapia
GEP20156250B (en) 2009-06-26 2015-02-25 Novartis Ag 1,3-disubstituted imidazolidin-2-one derivatives as inhibitors of cyp 17
JP2012532925A (ja) * 2009-07-16 2012-12-20 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 癌の処置のための化合物および方法
WO2012035078A1 (en) 2010-09-16 2012-03-22 Novartis Ag 17α-HYDROXYLASE/C17,20-LYASE INHIBITORS
US20120116381A1 (en) 2010-11-05 2012-05-10 Houser Kevin L Surgical instrument with charging station and wireless communication
EA023064B1 (ru) 2011-04-28 2016-04-29 Новартис Аг ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
US9801844B2 (en) * 2012-05-24 2017-10-31 The Research Foundation Of The City University Of New York Methods and compositions for the treatment of cancer
EA030128B1 (ru) 2012-09-26 2018-06-29 Арагон Фармасьютикалз, Инк. Способ лечения неметастатического кастрационно-резистентного рака простаты
WO2014058785A1 (en) 2012-10-10 2014-04-17 Novartis Ag Combination therapy
JOP20200097A1 (ar) * 2013-01-15 2017-06-16 Aragon Pharmaceuticals Inc معدل مستقبل أندروجين واستخداماته
CN105473147A (zh) 2013-04-24 2016-04-06 萨克生物研究学院 维生素d受体/smad基因组回路门纤维化反应
JP2016530219A (ja) 2013-06-05 2016-09-29 ソーク インスティテュート フォー バイオロジカル スタディーズ Ｃｘｃｌ１２活性に関与する疾患を処置するためのビタミンｄ受容体アゴニスト
WO2019023149A1 (en) 2017-07-24 2019-01-31 Salk Institute For Biological Studies USE OF BROMODOMAIN-CONTAINING PROTEIN-9 ANTAGONISTS IN ASSOCIATION WITH VITAMIN D RECEPTOR AGONISTS IN THE TREATMENT OF DIABETES
NZ763947A (en) 2017-10-16 2025-12-19 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of non-metastatic castration-resistant prostate cancer

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120722A (en) 1984-02-08 1992-06-09 Hoffmann-La Roche Inc. Trihydroxy-cholecacliferol and trihydroxy-ergocalciferol for treating leukemia
US4857518A (en) 1984-10-04 1989-08-15 Wisconsin Alumni Research Foundation Hydroxylated 24-homo-vitamin D derivatives and methods for preparing same
US4717721A (en) 1985-05-30 1988-01-05 Howard W. Bremer Sidechain homo-vitamin D compounds with preferential anti-cancer activity
KR940010767B1 (ko) 1985-08-02 1994-11-11 레오 파마슈티칼스 프로덕츠 리미티드 에이/에스(레벤스 케미스케 파브리크 프로덕션 사크티에셀스카브) 신규 비타민 d 동족체
US5145846A (en) 1988-01-20 1992-09-08 Hoffmann-La Roche Inc. Vitamin D3 analogs
US4851401A (en) 1988-07-14 1989-07-25 Wisconsin Alumni Research Foundation Novel cyclopentano-vitamin D analogs
CA1333616C (en) 1989-03-09 1994-12-20 Hector F. Deluca 19-nor-vitamin d compounds
GB8915770D0 (en) 1989-07-10 1989-08-31 Leo Pharm Prod Ltd Chemical compounds
DE4101953A1 (de) 1991-01-19 1992-07-23 Schering Ag 23-oxa-derivate in der vitamin-d-reihe, verfahren zu ihrer herstellung diese derivate enthaltende pharmazeutische praeparate sowie deren verwendung als arzneimittel
DE4141746A1 (de) 1991-12-13 1993-06-17 Schering Ag 20-methyl-substituierte vitamin d-derivate
DE69327096T2 (de) * 1992-03-31 2000-06-21 Btg International Ltd., London 17-substituierte steroide, verwendbar bei behandlung von krebs
US5604213A (en) 1992-03-31 1997-02-18 British Technology Group Limited 17-substituted steroids useful in cancer treatment
US5547947A (en) 1993-03-11 1996-08-20 Hoffmann-La Roche Inc. Methods of treatment
GB9622590D0 (en) 1996-10-30 1997-01-08 Leo Pharm Prod Ltd Chemical compounds
ATE515265T1 (de) 1998-03-27 2011-07-15 Univ Oregon Health & Science Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
WO2001064251A2 (en) * 2000-03-02 2001-09-07 University Of Pittsburgh Of The Commonwealth System Of Higher Education Combination chemotherapy
US7094775B2 (en) * 2004-06-30 2006-08-22 Bone Care International, Llc Method of treating breast cancer using a combination of vitamin D analogues and other agents

Similar Documents

Publication Publication Date Title
JP2010501576A5 (enExample)
JP2010501575A5 (enExample)
JP6740497B2 (ja) 癌を治療するための方法及び組成物
JP2012082215A5 (enExample)
US9370526B2 (en) Combination hormone replacement therapy (HRT) and melatonin to prevent and treat mammary cancer
ES2356408T3 (es) Medicamento que incluye al menos un gestágeno.
IL320452A (en) Combination therapy for prostate cancer
HRP20110129T1 (hr) Sastavi koji sadrže kristalni trans-(+/-)-delta-9-tetrahidrokanabinol
JP2020516646A5 (enExample)
US20030092638A1 (en) Protopanaxadiol and protopanaxatriol and their use as anti-cancer agents
JP2017516802A5 (enExample)
TWI422377B (zh) 用於促進抗癌治療活性之方法及組成物
JP2009511590A5 (enExample)
TWI441639B (zh) 用於治療卵巢癌之包含紫杉醇之組合
US6759397B2 (en) Ginsenoside chemotherapy
CN1652799A (zh) 只用抑制硫酸酯酶的孕激素的避孕给药方案
JP2010504307A5 (enExample)
US20100303937A1 (en) Novel composition to increase testosterone levels
JP2019513706A5 (enExample)
CN118045089A (zh) 呋喹替尼的药物制剂及其应用
CN115300624A (zh) 人参皂苷联合pd-1阻断剂在制备抗头颈鳞癌药物中的应用
US20050171071A1 (en) Menstrual cycle control and improvement of conception rates in females
CN101416959A (zh) 15-亚甲基取代穿心莲内酯衍生物在制备抗炎解热镇痛药物中的用途
JP2019535830A5 (enExample)
JP2006508071A5 (enExample)